Halozyme
Develops technologies for subcutaneous delivery of biopharmaceutical drugs.
Company facts
- Founded
- 1998
- Employees
- 423
- Headquarters
- United States
- CEO
- Helen Torley
- Type
- Public
- Listed
- NASDAQ: HALO
- Subsidiaries
- Halozyme Hypercon, Antares Pharma, Surf Bio
About
Halozyme Therapeutics is a biotechnology company that focuses on the development and commercialization of innovative therapies for human health. Founded with the vision to enhance the effectiveness of therapies by improving the delivery and absorption of drugs, Halozyme has made significant contributions to the field of therapeutics. Their proprietary product, Hylenex, is an enzyme that facilitates the distribution and absorption of injected drugs, thereby improving patient outcomes. The company is also well-known for its collaboration with major pharmaceutical companies, leveraging its ENHANZE drug delivery technology to enhance the performance of biologics. With a commitment to research and development, Halozyme continues to explore new treatments for various diseases, solidifying its position in the biotechnology industry as a leader in drug delivery solutions.